Literature DB >> 32574367

Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism.

Juan José Yepes-Nuñez1,2, Anita Rajasekhar3, Maryam Rahman4, Philipp Dahm5, David R Anderson6, Luis Enrique Colunga-Lozano1, Stephanie Ross7, Meha Bhatt1, Kelly Estrada Orozco8, Federico Popoff9, Matthew Ventresca1, Angela M Barbara1, Sara Balduzzi1, Housne Begum1, Arnav Agarwal1, Wojtek Wiercioch1, Robby Nieuwlaat1, Gian Paolo Morgano1, Holger J Schünemann1,10.   

Abstract

The impact of pharmacologic prophylaxis for venous thromboembolism in patients undergoing neurosurgical intervention remains uncertain. We reviewed the efficacy and safety of pharmacologic compared with nonpharmacologic thromboprophylaxis in neurosurgical patients. Three databases were searched through April 2018, including those for randomized controlled trials (RCTs) and for nonrandomized controlled studies (NRSs). Independent reviewers assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Seven RCTs and 3 NRSs proved eligible. No studies reported on symptomatic proximal and distal deep vein thrombosis (DVT). Two RCTs reported on screening-detected proximal and distal DVTs. We used the findings of these 2 RCTs as the closest surrogate outcomes to inform the proximal and distal DVT outcomes. These 2 RCTs suggest that pharmacologic thromboprophylaxis may decrease the risk of developing asymptomatic proximal DVT (relative risk [RR], 0.50; 95% confidence interval [CI], 0.30-0.84; low certainty). Findings were uncertain for mortality (RR, 1.27; 95% CI, 0.57-2.86; low certainty), symptomatic pulmonary embolism (PE) (RR, 0.84; 95% CI, 0.03-27.42; very low certainty), asymptomatic distal DVT (RR, 0.54; 95% CI, 0.27-1.08; very low certainty), and reoperation (RR, 0.43; 95% CI, 0.06-2.84; very low certainty) outcomes. NRSs also reported uncertain findings for whether pharmacologic prophylaxis affects mortality (RR, 0.72; 95% CI, 0.46-1.13; low certainty) and PE (RR, 0.18; 95% CI, 0.01-3.76). For risk of bleeding, findings were uncertain in both RCTs (RR, 1.57; 95% CI, 0.70-3.50; low certainty) and NRSs (RR, 1.45; 95% CI, 0.30-7.12; very low certainty). In patients undergoing neurosurgical procedures, low certainty of evidence suggests that pharmacologic thromboprophylaxis confers benefit for preventing asymptomatic (screening-detected) proximal DVT with very low certainty regarding its impact on patient-important outcomes.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32574367      PMCID: PMC7322965          DOI: 10.1182/bloodadvances.2020002195

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  37 in total

Review 1.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

3.  Pharmacological prophylaxis for deep vein thrombosis in acute spinal cord injury: an Indian perspective.

Authors:  T A Halim; H S Chhabra; M Arora; S Kumar
Journal:  Spinal Cord       Date:  2014-05-13       Impact factor: 2.772

4.  Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study.

Authors:  S Constantini; A Kanner; A Friedman; Y Shoshan; Z Israel; E Ashkenazi; M Gertel; A Even; Y Shevach; M Shalit; F Umansky; Z H Rappaport
Journal:  J Neurosurg       Date:  2001-06       Impact factor: 5.115

5.  The utility of screening for deep venous thrombosis in asymptomatic, non-ambulatory neurosurgical patients.

Authors:  Meghan Dermody; Jean Alessi-Chinetti; Mark D Iafrati; James M Estes
Journal:  J Vasc Surg       Date:  2011-01-07       Impact factor: 4.268

6.  Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors.

Authors:  L D Dickinson; L D Miller; C P Patel; S K Gupta
Journal:  Neurosurgery       Date:  1998-11       Impact factor: 4.654

7.  Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.

Authors:  G Agnelli; F Piovella; P Buoncristiani; P Severi; M Pini; A D'Angelo; C Beltrametti; M Damiani; G C Andrioli; R Pugliese; A Iorio; G Brambilla
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

8.  GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence.

Authors:  Holger J Schünemann; Carlos Cuello; Elie A Akl; Reem A Mustafa; Jörg J Meerpohl; Kris Thayer; Rebecca L Morgan; Gerald Gartlehner; Regina Kunz; S Vittal Katikireddi; Jonathan Sterne; Julian Pt Higgins; Gordon Guyatt
Journal:  J Clin Epidemiol       Date:  2018-02-09       Impact factor: 6.437

9.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.

Authors:  Jonathan Ac Sterne; Miguel A Hernán; Barnaby C Reeves; Jelena Savović; Nancy D Berkman; Meera Viswanathan; David Henry; Douglas G Altman; Mohammed T Ansari; Isabelle Boutron; James R Carpenter; An-Wen Chan; Rachel Churchill; Jonathan J Deeks; Asbjørn Hróbjartsson; Jamie Kirkham; Peter Jüni; Yoon K Loke; Theresa D Pigott; Craig R Ramsay; Deborah Regidor; Hannah R Rothstein; Lakhbir Sandhu; Pasqualina L Santaguida; Holger J Schünemann; Beverly Shea; Ian Shrier; Peter Tugwell; Lucy Turner; Jeffrey C Valentine; Hugh Waddington; Elizabeth Waters; George A Wells; Penny F Whiting; Julian Pt Higgins
Journal:  BMJ       Date:  2016-10-12

10.  Is chemical antithrombotic prophylaxis effective in elective thoracolumbar spine surgery? Results of a systematic review.

Authors:  James M Schuster; Dena Fischer; Joseph R Dettori
Journal:  Evid Based Spine Care J       Date:  2010-08
View more
  2 in total

1.  A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban.

Authors:  Zi-Yan Wang; You-Dong Wan; Xian-Zhi Liu; Hao Wang; Guang-Yi Jiang; Bo Yang
Journal:  Med Sci Monit       Date:  2022-02-10

2.  Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization.

Authors:  Ming Y Lim; Jeffrey A Gilreath
Journal:  Blood Adv       Date:  2020-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.